Sanofi has announced that it will lower the list price of its insulin drug, Lantus, by 78 percent and will set a $35 cap on out-of-pocket costs for all patients.
The price change and cap will go into effect starting January 1, 2024. They follow a series of moves made last year to lower the price of diabetes medicine, including the launch of an unbranded version of Lantus and a $35 cap for uninsured patients.
Yet, Olivier Bogillot, head of U.S. general medicines at Sanofi, said "the health system was unable to take advantage of it due to its inherent structural challenges."
“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years," he said. "Our decision to cut the list price of our lead insulin needs to be coupled with broader change to the overall system to actually drive savings for patients at the pharmacy counter.”
Sanofi will also cut the price of short-acting Apidra by 70 percent.
The incoming Fed decision will likely be good news for consumers with high-yield saving options, but bad news for borrowers (like anyone with high credit debt).
Empower your financial future with 'Investing Is Your Superpower' by Shinobu Hindert. Learn how to take control of your finances. No economics degree required
Inflation is still high, and economic activity is starting to slow down. But before you start to panic about stagflation, wait to see this week’s jobs report.
With buildings responsible for over 40% of emissions worldwide, the CEO of Kelvin breaks down how its technology can be used to retrofit traditional radiators.
After battling inflation for years, now U.S. consumers have to prepare for stagflation, and, unfortunately, it could be more complicated to fix than a typical
